Skip to main navigation Skip to search Skip to main content

Time from Prior Chemotherapy Enhances Prognostic Risk Grouping in the Second-line Setting of Advanced Urothelial Carcinoma: A Retrospective Analysis of Pooled, Prospective Phase 2 Trials

  • Guru Sonpavde
  • , Gregory R Pond
  • , Ronan Fougeray
  • , Toni K Choueiri
  • , Angela Q Qu
  • , David J Vaughn
  • , Guenter Niegisch
  • , Peter Albers
  • , Nicholas D James
  • , Yu-Ning Wong
  • , Yoo-Joung Ko
  • , Srikala S Sridhar
  • , Matthew D Galsky
  • , Daniel P Petrylak
  • , Ulka N Vaishampayan
  • , Awais Khan
  • , Nicholas J Vogelzang
  • , Tomasz M Beer
  • , Walter M Stadler
  • , Peter H O'Donnell
  • Cora N Sternberg, Jonathan E Rosenberg, Joaquim Bellmunt

Research output: Contribution to journalArticlepeer-review

78 Citations (Scopus)

Abstract

BACKGROUND: Outcomes for patients in the second-line setting of advanced urothelial carcinoma (UC) are dismal. The recognized prognostic factors in this context are Eastern Cooperative Oncology Group (ECOG) performance status (PS) >0, hemoglobin level (Hb) 0, LM, Hb 0, Hb
Original languageEnglish
JournalEuropean urology
DOIs
Publication statusPublished - 2012

Fingerprint

Dive into the research topics of 'Time from Prior Chemotherapy Enhances Prognostic Risk Grouping in the Second-line Setting of Advanced Urothelial Carcinoma: A Retrospective Analysis of Pooled, Prospective Phase 2 Trials'. Together they form a unique fingerprint.

Cite this